Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
4.240
-0.060 (-1.40%)
Nov 14, 2025, 4:00 PM EST - Market closed
Solid Biosciences Employees
Solid Biosciences had 100 employees as of December 31, 2024. The number of employees increased by 12 or 13.64% compared to the previous year.
Employees
100
Change (1Y)
12
Growth (1Y)
13.64%
Revenue / Employee
n/a
Profits / Employee
-$1,671,350
Market Cap
330.34M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 100 | 12 | 13.64% |
| Dec 31, 2023 | 88 | 1 | 1.15% |
| Dec 31, 2022 | 87 | -17 | -16.35% |
| Dec 31, 2021 | 104 | 34 | 48.57% |
| Dec 31, 2020 | 70 | -51 | -42.15% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SLDB News
- 4 days ago - Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 9 days ago - Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy - GlobeNewsWire
- 11 days ago - Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 12 days ago - Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions - GlobeNewsWire
- 6 weeks ago - Solid Biosciences to Present at Upcoming Scientific Meetings - GlobeNewsWire
- 7 weeks ago - Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting - GlobeNewsWire
- 7 weeks ago - Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101 - GlobeNewsWire
- 7 weeks ago - Kinea Bio Secures $1.1M Jain Foundation Investment and Solid Biosciences Capsid License to Advance Novel Gene Therapy for Dysferlinopathy, a Rare Neuromuscular Disease - Business Wire